In vitro activity of ceftobiprole against select Gram-positive and Gram-negative pathogens isolated from Europe in 20062007
Abstract number: P613
Torres M., Draghi D., Brown N., Thornsberry C., Sahm D., Pillar C.
Objective: Ceftobiprole (BPR) is a pyrrolidinone-3-ylidene-methyl cephalosporin with activity against a broad spectrum of clinically relevant pathogens, including meticillin-resistant S. aureus (MRSA). BPR is intended for use in hospitals against infections where resistant Gram-positive (GP) and Gram-negative (GN) bacteria, particularly MRSA, are suspected. As such, BPR is currently being developed to treat hospital-acquired pneumonia (HAP) and complicated skin and skin structure infections (cSSSI). The current surveillance initiative assessed the in vitro activity of BPR and comparator agents against GP and GN European (EU) clinical isolates from the past year.
Methods: During 2006 and 2007, GP (S. aureus [SA], coagulase-negative staphylococci [CoNS], and S. pneumoniae [SP]) and GN (Enterobacteriaceae [EN] and P. aeruginosa [PA]) clinical isolates were collected from 28 laboratories in 11 EU countries. All isolates were centrally tested by broth microdilution at Eurofins Medinet, Inc. (CLSI; M7A7).
Results: Against the tested SA, the MICs of BPR were similar to those of vancomycin and linezolid by MIC90 of 1 mg/L and 2 mg/L, respectively. BPR MICs against MRSA were 2 mg/L with the exception of 1.3% of MRSA isolates which had BPR MICs of 4 mg/L. Against EN and PA, BPR was similar to cefepime (FEP) by both MIC50/MIC90 (FEP: 0.06/4 mg/L for EN and 4/16 mg/L for PA).
Conclusion: BPR had potent in vitro activity against the tested GP pathogens, regardless of resistance to meticillin or PEN. BPR was comparable to FEP against both CAZ S and CAZ NS of EN and PA, though MICs of both FEP and BPR were elevated against the CAZ NS isolates. These results show the potential of BPR for the treatment of HAP and cSSSIs. As BPR is intended for use in hospitals where resistance is common, continued surveillance of BPR activity against target pathogens is warranted.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|